Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M

$PRLD

Earnings Per Share (GAAP)

$-1.29

vs $-0.18 est. (wider loss, 616.7%)

Revenue

$12.1M

estimate N/A

Loss widens sharply. Prelude Therapeutics Inc (NASDAQ: PRLD) reported a loss of $1.29 per share for Q4 2025, wider than the expected loss of $0.18 per share. The biotech posted a net loss of $99.5 million and operating loss of $104.6 million for the quarter. The $1.11 per-share gap represents a 616.7% wider loss than consensus anticipated, a significant deterioration from Q3 2025 when the company posted a loss of just $0.26 per share that beat estimates by 26.8%.

Revenue jumps sequentially. The company generated revenue of $12.1 million for the quarter, up 86.5% from $6.5 million in Q3 2025. The prior two quarters of fiscal 2025 saw zero revenue, making Q4’s $12.1 million a notable inflection. With a market capitalization of $194.3 million and shares trading at $3.23, the stock showed minimal movement on 285,422 shares of volume following the before-market-open release.

What to Watch: The company filed an 8-K press release with details on the quarter. Investors should scrutinize the 10-K filing for explanations of the outsized loss—whether driven by R&D spending, clinical trial costs, or one-time charges—and any commentary on the sustainability of the revenue stream that emerged in the second half of fiscal 2025.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.